The articles on pancreatic cancer chemotherapy regimens are as numerous as a sweatshop, so I will not repeat them here. We will publish some small insights from time to time, combining our personal clinical experience, for the reference of related friends. Suggestions on adjuvant chemotherapy after pancreatic cancer surgery. The standard chemotherapy regimen for pancreatic cancer after radical surgery is still inconclusive, and it is customary to apply gemcitabine single-agent 1,8 regimen for six cycles of chemotherapy in clinical practice. Recent data from Japanese studies suggest that S1 has shown clinical benefit over gemcitabine alone in the Japanese population. Since the above studies are based on traditional population studies, what should be the choice for individualized clinical treatment? Personally, I suggest that for patients undergoing radical pancreatic cancer surgery, fresh specimens should be collected and tested for drug sensitivity genes (RRM1, TYMS) as much as possible after surgery, so as to determine which drug is best for patients based on the level of the test.